(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -3.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Arcus Biosciences's revenue in 2024 is $237,000,000.On average, 4 Wall Street analysts forecast RCUS's revenue for 2024 to be $21,817,080,655, with the lowest RCUS revenue forecast at $9,095,301,100, and the highest RCUS revenue forecast at $44,065,824,299. On average, 4 Wall Street analysts forecast RCUS's revenue for 2025 to be $12,341,050,251, with the lowest RCUS revenue forecast at $9,095,301,100, and the highest RCUS revenue forecast at $18,372,508,222.
In 2026, RCUS is forecast to generate $22,769,995,351 in revenue, with the lowest revenue forecast at $9,095,301,100 and the highest revenue forecast at $51,970,277,626.